This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MarketVIEW: Acne Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Acne vaccines

Acne vulgaris is a common skin condition which is estimated to affect 80% of people at some point between 11 and 30 years of age. The condition ranges from mild to severe with latter more likely to cause scarring and psychological impact such as depression, loss of self esteem and in extreme cases, suicidal ideation. Acne is responsible for a significant number of yearly physician office visits and direct costs for treatments which range from OTC lotions to prescription based antibiotics/retinoids. 

An acne vaccine targeting the main causative bacterium P.acnes could have wide utility if it prevents inflammatory outbreaks in individuals suffering from acne. Indeed, the major vaccine manufacturer Sanofi Pasteur has already announced interest in this concept ( University of San Diego collaboration) confirming its potential attractiveness. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of acne vaccines (value/volume) to 2030 in the Western region. The product examines different uptake scenarios of the vaccine in severe and non-severe patient groups at different age range(s). Detailed coverage of latest acne epidemiology is included, also a focus on current treatment pathways, costs and the need for a novel vaccine approach. This product is an essential component of any new internal exercise assessing the potential of new acne vaccines. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL Contents – Executive presentation (MS PowerPoint based)Title PageContentsAuthor's notesExecutive SummaryCommercial model: key outputsAcne vaccine: available market ($ 000s) to 2030 (severe patients)Acne vaccine: predicted volume (doses 000s) to 2030 (severe patients)Acne vaccine: available market ($ 000s) to 2030 per country (severe patients)Acne vaccine: available market ($ 000s) to 2030 (all patients)Acne vaccine: predicted volume (doses 000s) to 2030 (all patients)Acne vaccine: available market ($ 000s) to 2030 (BASE SCENARIO)Acne vaccine: predicted volume (doses 000s) to 2030 (BASE SCENARIO)Acne Vulgaris: disease background and epidemiologyAcne: brief disease backgroundAcne: clinical typesAcne: global epidemiologyAcne: adult acne statisticsAcne: impact of the diseaseAcne: treatment pathwayAcne: treatment overviewAcne: treatment optionsAcne: effectiveness of treatment in mild and moderate casesAcne: effectiveness of treatment in severe casesAcne: cost of treatmentAcne: cost of treatment in the USAcne vaccine; target product profile (TPP)The role of an acne vaccineCurrent status of the vaccinePipeline summaryAddressable vaccine populationsAcne vaccine forecast modelForecast vaccine population flowAcne vaccine: target product profileCommercial model assumptionsDetailed commercial model assumptions by country (LO uptake)Detailed commercial model assumptions by country (BASE uptake)Acne vaccine: other target populationsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: ~50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)Note: further models can be included with differing vaccine price scenariosTitle pageTOTAL CHARTS (ALL PATIENTS)TOTAL CHARTS (severe only)BASE (severe versus non-severe)CHARTS – VAL HIGH (severe only)CHARTS – VAL BASE (severe only)CHARTS – VAL LOW (severe only)CHARTS – VOL HIGH (severe only)CHARTS – VOL BASE (severe only)CHARTS – VOL LOW (severe only)VALUE SUMMARY (severe only)VOLUME SUMMARY (severe only)VALUE SUMMARY (ALL PATIENTS)VOLUME SUMMARY (ALL PATIENTS)Country worksheets =>>USCANADAUKFRANCEGERMANYITALYSPAINAUSTRALIAJAPANAssumptionsWorksheets = 44 per model

To order this report:: MarketVIEW: Acne vaccines

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 1.05%
FB $99.75 -4.15%
GOOG $682.74 -0.12%
TSLA $147.99 -8.99%
YHOO $27.05 -3.29%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs